Neuphoria Therapeutics Inc. cash flow statement NEUP

Annual Quarterly

In fiscal 2026, which ended Jun 30, 2026, Neuphoria Therapeutics Inc. used $12.4 million of cash from operations, down 16095.4% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Jun 30, 2025
FY 2024
Jun 30, 2024
Operating
Depreciation and amortization
1
+0.0%
1
-0.0%
1
Stock-based compensation
0
+114.7%
0
-79.9%
1
Operating cash flow
-12
-16095.4%
0
+100.5%
-15
Financing
Financing cash flow
18
+1072.3%
2
-89.9%
15
Change in cash
Effect of exchange rate
0
+474.2%
-0
-104.9%
0
Net change in cash
6
+248.2%
2
—
Ratios
Stock-based compensation to revenue
29.94%
1.05%
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NEUP (Nasdaq)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Burlington, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1191070
Former names
BIONOMICS LIMITED/FI (until Dec 23, 2024)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.